Skip to content
IP + Technology Law
Home  »  News & Insights  »  News

Partner Brent Babcock Discusses New CRISPR IP Alliance

December 19, 2016  | Brenton R. Babcock

Partner Brent Babcock, Chair of the firm’s USPTO Trials & Post-Grant Proceedings group, was quoted in “Some Consensus in the CRISPR Patent Case,” an article published in MedCity News. The article discuses four companies founded in the CRISPR space that announced last Friday, December 16, that they had formed an IP alliance.

Read the article here

 

Related Links

Industries

News & Insights

Blog - Biotechnology
Mar 2026
New FDA Guidance Allows Biosimilar Applicants to Use Data From Outside the U.S. To Accelerate Their Approval in the U.S.
Key Takeaway: New FDA guidance released on February 23, 2026, and March 9, 2026, signals a continued shift toward regulatory flexibility aimed at accelerating approval of biosimilar treatments for rare...
Blog - Biotechnology
Mar 2026
AI and Genomics: A New Era of Personalized Medicine
Key Takeaway: Advances in AI and genomic analysis will allow medical providers to tailor treatment for individual patients at the genome level, but challenges exist for protecting AI-assisted inventions. Genomic...
Blog - Aerospace
Feb 2026
Staking Claims Among the Stars: Patent Protection in the New Space Economy
Key Takeaway: Due to the lower barrier to entry to space, companies that file patents in this developing field now will not only protect their investments but secure an early,...